Aramark ARMK 深 沪
等待开盘 10-21 09:30:00 美东时间
38.76
+0.030
+0.08%
华盛通- 最 高39.07
- 今 开38.86
- 成交量 358.16万股
- 最 低 38.61
- 昨 收 38.73
- 总市值 101.94亿
- 52周最高 44.385
- 市盈率 静 39.30
- 换手率 1.36%
- 52周最低 29.71
- 委 比 42.86%
- 总股本 2.63亿
- 历史最高 44.385
- 量 比 1.44
- 振 幅 1.19%
- 历史最低 -2.34
- 每 手 1
- 风险率 2.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Armada Hoffler Announces Appointment of Shawn J. Tibbetts as Chairman of the Board of Directors
Armada Hoffler's Board of Directors has appointed Shawn J. Tibbetts as Chairman of the Board, effective January 1, 2026. Tibbetts, who has been CEO since 2019, will continue leading the company. The move unites the roles of CEO and Chairman, reflecting the Board's confidence in Tibbetts’ leadership and commitment to growth and shareholder value. Lou Haddad will step down as Chairman but remain a Board member. This transition aims to enhance effic...
10-16 10:15
Is Aramark Gaining or Losing Market Support?
Aramark's (NYSE:ARMK) short interest as a percent of float has fallen 5.24% sin...
10-09 23:02
Aramark And The University Of Pennsylvania Health System Enters New Multi-Year Agreement To Provide Services Across UPHS's Seven-Hospital Nearly 4,000-Bed System
Aramark (NYSE:ARMK) and the University of Pennsylvania Health System (UPHS) today announced a new multi-year agreement beginning in early 2026 to provide patient and retail food, environmental services, patient
10-09 04:34
美股大行评级 | 潜在涨幅162.68%！Ocular Therapeutix获JMP证券升目标价至29美元，维持"跑赢大市"评级
今日重点评级关注：JMP证券：维持Ocular Therapeutix"跑赢大市"评级，目标价从20美元升至29美元；汇丰银行：上调Banco BBVA Argentina评级至"买入"，目标价从21美元下调至17美元
10-02 15:08
UBS Maintains Buy on Aramark, Lowers Price Target to $45
UBS analyst Joshua Chan maintains Aramark (NYSE:ARMK) with a Buy and lowers the price target from $46 to $45.
10-01 21:22
Cava Group Earnings Preview
Cava Group (NYSE:CAVA) is set to give its latest quarterly earnings report on T...
08-11 22:02
Earnings Preview: Texas Roadhouse
Texas Roadhouse (NASDAQ:TXRH) is preparing to release its quarterly earnings on...
08-07 00:07
UBS Maintains Buy on Aramark, Raises Price Target to $46
UBS analyst Joshua Chan maintains Aramark (NYSE:ARMK) with a Buy and raises the price target from $44 to $46.
08-06 22:46
Aramark shares are trading lower after the company reported a Q3 sales miss.
Aramark shares are trading lower after the company reported a Q3 sales miss.
08-05 20:20
Aramark misses top-line estimates; reaffirms FY25 outlook
Aramark press release (NYSE:ARMK): Q3 Non-GAAP EPS of $0.40 in-line. Revenue of $4.63B (+5.7% Y/Y) misses by $30M. Organic Revenue +5%. The Company continues to anticipate its full-year performance fo...
08-05 18:42
